Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity
Open Access
- 24 July 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (5) , 1152-1160
Abstract
CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing drugs. The objective of this study was to determine how sub‐Saharan African‐specific CYP2D6*17 and *29 alleles affect risperidone metabolism. To do this, we generated the largest real‐world cohort of risperidone users in an African study population for pharmacogenetic studies. Risperidone users ≤ 18 years old were recruited from the Federal Neuro‐Psychiatric Hospital. Health records were obtained by parent report and paper charts. CYP2D6 genotyping was performed for > 20 variants. Plasma concentrations of risperidone and 9‐hydroxyrisperidone were determined by liquid chromatography mass spectrometry. CYP2D6 activity was calculated based on the metabolic ratio 9‐hydroxyrisperidone:risperidone. Multivariable linear regression modeling was performed to determine the association between our alleles of interest and log‐transformed ratio‐defined CYP2D6 activity relative to star alleles with established activity values. Across 208 enrolled participants, CYP2D6 activity value for *17 was found to be twice that of normal function alleles, while *29 was comparable to no function alleles. These results contrast previous values assigned to *17 and *29 from guidelines, which are not based on evidence with risperidone, suggesting the possibility of substrate specificity for these alleles. Ultimately, our findings have the potential to improve risperidone prescribing, especially for patient groups with substantial sub‐Saharan African ancestry. Importantly, this work underscores the critical need to better understand the effects of ancestry‐specific alleles for achieving equitable pharmacotherapeutic health outcomes.Keywords
This publication has 44 references indexed in Scilit:
- SLCO1B1 Functional Variants, Bilirubin, Statin‐Induced Myotoxicity, and Recent Sub‐Saharan African Ancestry: A Precision Medicine Health Equity StudyClinical Pharmacology & Therapeutics, 2025
- Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity LensClinical Pharmacology & Therapeutics, 2023
- Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of BrexpiprazoleClinical Pharmacology & Therapeutics, 2022
- CYP2D6*9 and *41: Does the Activity Value Assigned to these Alleles Need to be Reduced to more Accurately Predict Phenotype?Clinical Pharmacology & Therapeutics, 2021
- Overcoming Historical Barriers: Enhancing Positive Perceptions of Medical Research Among African Americans Through a Conference-Based WorkshopJournal of General Internal Medicine, 2021
- Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetineCPT: Pharmacometrics & Systems Pharmacology, 2021
- Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 SubstratesClinical Pharmacology & Therapeutics, 2021
- Safety of 80 antidepressants, antipsychotics, anti‐attention‐deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta‐review of 78 adverse effectsWorld Psychiatry, 2020
- Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of ratPsychopharmacology, 1998
- Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean populationEuropean Journal of Clinical Pharmacology, 1996